



## Technology & Research

### *Investing in formulation as success' factor*

Early formulation studies pose many challenges but represent a critical point to reduce the time-to-market needed to make available a new medicinal product to patients. Poor solubility of the active ingredient is often a main issue to be faced, together with the optimisation of its stability, bioavailability and manufacturability

[>>](#)



## Regulatory Affairs

### *Revision of the CDMh's Q&As document on nitrosamine impurities*

Revision 5 of the CDMh document includes modification of terms for the lifting of Conditions B and D to the marketing authorisation. A Communication of the FDA specifies that formulation design strategies may represent a possible approach to limit the presence of nitrosamine impurities in the final medicinal product

[>>](#)



## Business & Policies

### *A record year for biotech investments in UK, a year after the Brexit*

A recent report published by the UK's BioIndustry Association (BIA) and Clarivate illustrates the trends of investment in the biotech sector in 2021. The country confirmed its high attractiveness for investors, both with regard to venture capitals and IPOs.

[>>](#)



## EU Focus

### *Faculty of Pharmacy is once again a part of Masaryk University*

The Faculty of Pharmacy of the Veterinary and Pharmaceutical University Brno was transferred back to the framework of Masaryk University (both are located in Brno, Czech Republic). This short communication discusses the background to this event.

[>>](#)



## News from EIPG

### *Continuous Manufacturing of Pharmaceuticals: Higher Quality, Greater Flexibility*

In EIPG's and PIER's next webinar, to be held on 30th March 2022 (17.00 CEST), Giustino Di Pretoro a subject matter expert and drug product development lead will provide his expert practical experience of continuous manufacturing.

[>>](#)